Fuji Film

(President: Kenji Sukeno) has announced the selection of Holly Springs, North Carolina as the location for its new large-scale cell culture production site in the United States. The previously announced investment of more than 200 Billion yen (2 Billion USD) to establish the largest end-to-end cell culture biopharmaceutical CDMO* facility in North America will create 725 highly-skilled jobs in the area by the end of 2028. The new facility will offer large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing.

Inc. (hereinafter “FFIC Inc.”), a U.S. subsidiary of FUJIFILM Corporation, will construct a new production plant for pigment dispersions, which is a colorant for water-based pigment inkjet inks, in order to accelerate the growth of the global inkjet business. By adding the new production plant for pigment dispersions (the main colorant in water-based pigment inkjet inks), it will be able to produce consistent, fully-featured water-based pigment inkjet inks built with Fujifilm's own core dispersion technology. Fujifilm uses RxD dispersions not only for its own inks, but also supplies to ink manufacturers around the world, and they are used in many water-based pigment inkjet inks. FUJIFILM Ink Solutions activities have the global team and facilities of expert to manage from R&D to manufacturing located in U.K., U.S., India and Japan to work across a network of dedicated technology development facilities and specialized manufacturing centers, capable of meeting the highest volume demands.

The investment also coincides with the signing of a business partnership agreement between the two companies, which gives Fujifilm the priority negotiation right for contract development and manufacturing of Cuorips' allogeneic iPSC-derived cardiomyocyte sheet in the United States. Fujifilm plans to use the therapeutic iPSC manufacturing facility (cGMP*4-compliant) of FUJIFILM Cellular Dynamics, Inc., its U.S. subsidiary and a leading developer and manufacturer of iPSC, to expand the contract development and manufacturing business for regenerative medicine products, such as cell therapeutics. Fujifilm will expand its drug discovery support business and promote contract development and manufacturing business for regenerative medicine products and effective R&D in collaboration with partners, thereby contribute to industrialization of regenerative medicine. About Fujifilm's regenerative medicine business Fujifilm is committed to expanding its business operations and contributing to the establishment of the regenerative medicine industry by utilizing an array of technologies including Fujifilm's own engineering technologies, nurtured and evolved through the development of broad-ranging products, with a diverse range of technologies held by its subsidiaries.

(President: Kenji Sukeno) is pleased to announce the launch of the “FUJIFILM PROJECTOR Z8000 (FP-Z8000)” in March, 2021, joining the lineup of the Z Series of ultra-short throw projectors equipped with the world's first “folded two-axial rotatable lens.” Fujifilm entered into the projector market in 2019 with the launch of “FUJIFILM PROJECTOR Z5000 (FP-Z5000),” equipped with a “folded two-axial rotatable lens” to project images to various directions without having to move the main unit. The use of the “folded two-axial rotatable lens” means the projector can throw images in various directions without having to move the main unit. Among ultra-short throw projectors equipped with a laser light source capable of projecting images in brightness of 8000lm or above (TR value of 0.4 or below) as of March 4, 2021 according to Fujifilm.